Ravi Patel, MD, PhD, discusses expanding theranostics access, personalized dosing strategies, and translational research in radiation oncology.
|Poll|November 11, 2015
NET Patient Undergoes MRI to Evaluate Response to Therapy
Author(s)Brian Morse, MD
A 63-year-old man with NET metastatic to the liver undergoes MRI for evaluation of response to therapy. Based on the imaging, what is your diagnosis?
Advertisement
A 63-year-old man with neuroendocrine tumor (NET) metastatic to the liver undergoes magnetic resonance imaging (MRI) for evaluation of response to therapy. The patient reports an episode of left upper quadrant pain (unrelated to trauma) that occurred several weeks earlier. Noncontrast (left) and postcontrast (right) T1-weighted images with fat suppression are available for review.
What is your diagnosis?
Advertisement
Related to this article
Jeffrey V. Matous, MD, discusses how to counsel patients on chronic, low-grade toxicities to support adherence to ramantamig.
The FDA approved adjuvant atezolizumab with chemotherapy for patients with resected stage III dMMR colon cancer based on results from the phase 3 ATOMIC trial.
“No one should be excluded from any clinical trial,” said Paul G. Rubinstein, MD, regarding patients with HIV-associated cancers in cooperative group studies.
Interim phase 2 data show a median PFS of 17.7 months with carotuximab plus apalutamide vs 2 months with apalutamide alone in metastatic CRPC.
Ahead of a fourth-quarter 2026 FDA decision, TALAPRO-3 investigators outline the testing, monitoring, and sequencing steps needed to adopt the regimen.
Iberdomide plus daratumumab/dexamethasone met the second dual primary end point of the phase 3 EXCALIBER-RRMM trial in relapsed/refractory multiple myeloma.
Melody Rasouli, MD, MBA, FACOG, explained how random-start ovarian stimulation and rapid sperm banking fit fertility preservation into cancer care.
Advertisement
Advertisement
Trending on CancerNetwork
1
FDA Approves Atezolizumab/Chemo for Stage III dMMR Colon Cancer
2
FDA Approves Tucatinib Combo as Maintenance in HER2+ Breast Cancer
3
Novel Cancer Vaccine Plus Temozolomide Miss Primary End Point in Glioblastoma
4
Considering Talquetamab and Emerging Bispecifics in R/R Multiple Myeloma
5